Your browser doesn't support javascript.
Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice.
Puhl, Ana C; Gomes, Giovanni F; Damasceno, Samara; Fritch, Ethan J; Levi, James A; Johnson, Nicole J; Scholle, Frank; Premkumar, Lakshmanane; Hurst, Brett L; Lee-Montiel, Felipe; Veras, Flavio P; Batah, Sabrina S; Fabro, Alexandre T; Moorman, Nathaniel J; Yount, Boyd L; Dickmander, Rebekah J; Baric, Ralph S; Pearce, Kenneth H; Cunha, Fernando Q; Alves-Filho, José C; Cunha, Thiago M; Ekins, Sean.
  • Puhl AC; Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States.
  • Gomes GF; Center for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto 14049-900, Sao Paulo, Brazil.
  • Damasceno S; Center for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto 14049-900, Sao Paulo, Brazil.
  • Fritch EJ; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States.
  • Levi JA; Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695-7001, United States.
  • Johnson NJ; Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695-7001, United States.
  • Scholle F; Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695-7001, United States.
  • Premkumar L; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States.
  • Hurst BL; Institute for Antiviral Research, Utah State University, Logan, Utah 84322-1400, United States.
  • Lee-Montiel F; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah 84322-1400, United States.
  • Veras FP; PhenoVista Biosciences, 6195 Cornerstone Ct E. #114, San Diego, California 92121, United States.
  • Batah SS; Center for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, University of Sao Paulo, Avenida Bandeirantes, 3900, Ribeirao Preto 14049-900, Sao Paulo, Brazil.
  • Fabro AT; Department of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14090900, Brazil.
  • Moorman NJ; Department of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14090900, Brazil.
  • Yount BL; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States.
  • Dickmander RJ; Rapidly Emerging Antiviral Drug Discovery Initiative, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, United States.
  • Baric RS; Center for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
  • Pearce KH; Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, United States.
  • Cunha FQ; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States.
  • Alves-Filho JC; Rapidly Emerging Antiviral Drug Discovery Initiative, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, United States.
  • Cunha TM; Center for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
  • Ekins S; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States.
ACS Omega ; 7(36): 31935-31944, 2022 Sep 13.
Article in English | MEDLINE | ID: covidwho-2185524
ABSTRACT
The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid, and molnupiravir), or in advanced clinical trials. Vandetanib is a kinase inhibitor which targets the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), as well as the RET-tyrosine kinase. In the current study, it was tested in different cell lines and showed promising results on inhibition versus the toxic effect on A549-hACE2 cells (IC50 0.79 µM) while also showing a reduction of >3 log TCID50/mL for HCoV-229E. The in vivo efficacy of vandetanib was assessed in a mouse model of SARS-CoV-2 infection and statistically significantly reduced the levels of IL-6, IL-10, and TNF-α and mitigated inflammatory cell infiltrates in the lungs of infected animals but did not reduce viral load. Vandetanib also decreased CCL2, CCL3, and CCL4 compared to the infected animals. Vandetanib additionally rescued the decreased IFN-1ß caused by SARS-CoV-2 infection in mice to levels similar to that in uninfected animals. Our results indicate that the FDA-approved anticancer drug vandetanib is worthy of further assessment as a potential therapeutic candidate to block the COVID-19 cytokine storm.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: ACS Omega Year: 2022 Document Type: Article Affiliation country: Acsomega.2c02794

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: ACS Omega Year: 2022 Document Type: Article Affiliation country: Acsomega.2c02794